Search Results for "Alnylam"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Givosiran: Stability in Prepared Syringe

Standard response letter the stability of givosiran in a prepared syringe.

Clinical outcomes in patients with acute hepatic porphyria treated with givosiran who stopped hemin prophylaxis at study entry: Post hoc analyses from the phase 3 ENVISION study through month 36

Real-World Treatment Patterns in Participants with Transthyretin Amyloidosis with Polyneuropathy Enrolled in the ConTTRibute Registry

Vutrisiran: Drug Interactions

Standard response letter on vutrisiran and drug interactions.

Vutrisiran: Dosage & Administration Schedule Used in Phase 3 Studies

Standard response letter on the dosing schedules of vutrisiran used in the HELIOS-A and HELIOS-B studies.

Givosiran: ENVISION Study 36-Month Results

Standard response letter on givosiran and the 36-month results of the ENVISION study, a phase 3 study evaluating the efficacy and safety of givosiran in patients with a documented diagnosis of AHP.

Givosiran: Hemin Use

Standard response letter on givosiran and hemin use. This medical information response contains clinical data from the ENVISION study.

Patisiran: Patients with Heart Transplant

Standard response letter on patisiran and use in patients with heart transplant.

Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6-months of givosiran treatment: a subgroup analysis of the phase 3 ENVISION study

Lumasiran: Use in Kidney Transplantation

Standard response letter on the use of lumasiran in patients who have had an isolated kidney transplant.

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.